{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+Tolterodine",
    "query": {
      "intervention": "Placebo to Tolterodine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+Tolterodine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T06:49:57.376Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07829029",
      "title": "Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPH",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Nocturia"
      ],
      "interventions": [
        {
          "name": "TolterodineTartrate ER",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "60 Years and older · Female only"
      },
      "enrollment_count": 270,
      "start_date": "2022-10-04",
      "completion_date": "2027-05-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-09-28T06:49:57.376Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07829029"
    },
    {
      "nct_id": "NCT05362292",
      "title": "TReating Incontinence for Underlying Mental and Physical Health",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urinary Incontinence, Urge",
        "Urinary Incontinence",
        "Overactive Bladder",
        "Incontinence, Urge",
        "Incontinence, Urinary",
        "Incontinence"
      ],
      "interventions": [
        {
          "name": "Tolterodine Tartrate ER",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "60 Years and older · Female only"
      },
      "enrollment_count": 270,
      "start_date": "2022-10-04",
      "completion_date": "2027-08-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-09-28T06:49:57.376Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • San Francisco, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05362292"
    },
    {
      "nct_id": "NCT01050114",
      "title": "OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "onaBoNT-A",
          "type": "DRUG"
        },
        {
          "name": "Oxybutynin ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Christopher Patrick Smith",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-08",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2016-08-30",
      "last_synced_at": "2026-09-28T06:49:57.376Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01050114"
    },
    {
      "nct_id": "NCT03583372",
      "title": "An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Vibegron",
          "type": "DRUG"
        },
        {
          "name": "placebos",
          "type": "DRUG"
        },
        {
          "name": "Tolterodine Tartrate ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Urovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 506,
      "start_date": "2018-06-14",
      "completion_date": "2019-07-25",
      "has_results": true,
      "last_update_posted_date": "2021-03-18",
      "last_synced_at": "2026-09-28T06:49:57.376Z",
      "location_count": 107,
      "location_summary": "Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 90 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03583372"
    },
    {
      "nct_id": "NCT01302054",
      "title": "A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urinary Bladder, Overactive"
      ],
      "interventions": [
        {
          "name": "Fesoterodine 8 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 990,
      "start_date": "2011-05",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2018-12-04",
      "last_synced_at": "2026-09-28T06:49:57.376Z",
      "location_count": 109,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 80 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Green Valley",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01302054"
    },
    {
      "nct_id": "NCT00282932",
      "title": "Detrol LA In Men With Overactive Bladder.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder (OAB)"
      ],
      "interventions": [
        {
          "name": "Detrol LA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "40 Years and older · Male only"
      },
      "enrollment_count": 600,
      "start_date": "2006-01",
      "completion_date": "2007-05-14",
      "has_results": false,
      "last_update_posted_date": "2021-01-27",
      "last_synced_at": "2026-09-28T06:49:57.376Z",
      "location_count": 11,
      "location_summary": "Anaheim, California • La Mesa, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00282932"
    },
    {
      "nct_id": "NCT00411437",
      "title": "Effects Of Detrol LA On Memory And Cognition In Elderly Population",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Memory",
        "Cognition"
      ],
      "interventions": [
        {
          "name": "Tolterodine ER",
          "type": "DRUG"
        },
        {
          "name": "Oxybutynin ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "65 Years to 75 Years"
      },
      "enrollment_count": 220,
      "start_date": "2006-12",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2021-01-27",
      "last_synced_at": "2026-09-28T06:49:57.376Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • Brooksville, Florida • DeLand, Florida + 5 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00411437"
    },
    {
      "nct_id": "NCT01302938",
      "title": "Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Tolterodine ER",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2011-03",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-09-28T06:49:57.376Z",
      "location_count": 2,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01302938"
    },
    {
      "nct_id": "NCT03492281",
      "title": "A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "vibegron",
          "type": "DRUG"
        },
        {
          "name": "Vibegron placebo",
          "type": "DRUG"
        },
        {
          "name": "Tolterodine Tartrate ER",
          "type": "DRUG"
        },
        {
          "name": "Tolterodine placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Urovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1530,
      "start_date": "2018-03-26",
      "completion_date": "2019-02-04",
      "has_results": true,
      "last_update_posted_date": "2021-03-04",
      "last_synced_at": "2026-09-28T06:49:57.376Z",
      "location_count": 191,
      "location_summary": "Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03492281"
    },
    {
      "nct_id": "NCT02138747",
      "title": "A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder (OAB)"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Tolterodine ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 376,
      "start_date": "2014-07-24",
      "completion_date": "2015-11-11",
      "has_results": true,
      "last_update_posted_date": "2020-02-26",
      "last_synced_at": "2026-09-28T06:49:57.376Z",
      "location_count": 22,
      "location_summary": "Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02138747"
    }
  ]
}